Economic issues with follow-on protein products
- 1 September 2008
- journal article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 7 (9) , 733-737
- https://doi.org/10.1038/nrd2636
Abstract
The economic effects of the possible introduction of 'follow-on' protein products have been the subject of recent debate. Here, we aim to explore the economic issues surrounding this debate using three measures: total sales, product complexity and patent expiry. Our analysis shows that the sales of therapeutic protein products are concentrated in a relatively small number of branded products, which may be the most attractive targets for follow-on development. For the years 2013-2015, we estimate that products representing US$20 billion in annual sales--approximately half of all sales in 2006--can be expected to lose patent protection.Keywords
This publication has 6 references indexed in Scilit:
- What's fueling the biotech engine?Nature Biotechnology, 2007
- The FDA's assessment of follow-on protein products: a historical perspectiveNature Reviews Drug Discovery, 2007
- The Market For Follow-On Biologics: How Will It Evolve?Health Affairs, 2006
- First generic biologics finally approvedNature Reviews Drug Discovery, 2006
- ‘Follow-On Biologics’: Ensuring Continued Innovation In The Biotechnology IndustryHealth Affairs, 2006
- Equivalence studies for complex active ingredients and dosage formsThe AAPS Journal, 2005